Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
08/14/2017 08/15/2017 08/16/2017 08/17/2017 08/18/2017 Date
287.6(c) 289(c) 286(c) 292(c) 285.7 Last
3 218 186 2 607 169 3 428 179 5 685 019 1 325 160 Volume
-0.72% +0.49% -1.04% +2.10% -2.16% Change
More quotes
Financials ( DKK)
Sales 2017 113 486 M
EBIT 2017 49 286 M
Net income 2017 38 254 M
Finance 2017 18 562 M
Yield 2017 2,65%
Sales 2018 117 853 M
EBIT 2018 50 816 M
Net income 2018 39 972 M
Finance 2018 18 449 M
Yield 2018 2,85%
P/E ratio 2017 18,90
P/E ratio 2018 17,62
EV / Sales2017 4,89x
EV / Sales2018 4,71x
Capitalization 573 069 M
More Financials
Company
Novo Nordisk AS engages in the research, development, manufacture, and marketing of pharmaceutical products.It operates through the Diabetes and Obesity Care, and Biopharmaceuticals segments.The Diabetes and Obesity Care segment covers insulins, glucagon-like-peptide 1, other protein-related... 
Sector
Pharmaceuticals
Calendar
09/11Presentation
More about the company
Surperformance© ratings of Novo Nordisk A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVO NORDISK A/S
08/17 NOVO NORDISK A/S : - Semaglutide superior to dulaglutide on glucose control and ..
08/17 ELI LILLY AND CO (NYSE : LLY) Tanks As Novo Nordisk A/S (ADR) (NYSE:NVO) Diabete..
08/16 NOVO NORDISK A/S : Semaglutide superior to dulaglutide on glucose control and we..
08/16 NOVO NORDISK A/S : Trading in Novo Nordisk Shares by Board Members, Executives a..
08/16 NOVO NORDISK A/S : - Share Repurchase Programme
08/16 NOVO NORDISK A/S : A S - Share repurchase programme
08/15DJWHEN 'NEW AND IMPROVED' FAILS : Insulin Maker -2-
08/15DJWHEN 'NEW AND IMPROVED' FAILS : Insulin Maker Stumbles When Customers Balk
08/15 NOVO NORDISK A/S : Changes in Novo Nordisk Executive Management
08/14 NOVO NORDISK A/S : A S - Trading in shares by board members, executives and asso..
More news
Sector news : Pharmaceuticals - NEC
08:35aDJASTRAZENECA : FDA Approves AstraZeneca's Ovarian Cancer Treatment Lynparza Table..
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/17 Drugmaker Hikma trims sales forecasts, shares fall
08/17 Exclusive - Taking aim at China, India tightens power grid, telecoms rules
08/16 Seven charged in U.S. insider trading ring
More sector news : Pharmaceuticals - NEC
Latest Tweets
07:58aNovo Nordisk's Semaglutide Shows Remarkable Results in Study -
1
05:52aNovo Nordisk's new semaglutide trounces Lilly's scrappy Trulicity in diabetes..
3
08/17Novo Nordisk's new semaglutide trounces Lilly's scrappy Trulicity in diabetes..
2
08/17Novo Nordisk's new semaglutide trounces Lilly's scrappy Trulicity in diabetes.. 
08/17CORRECTED-UPDATE 1-Novo Nordisk's diabetes drug succeeds in key trial (Aug 16.. 
More tweets
Qtime:65
News from SeekingAlpha
08/16 Novo's semaglutide beats Lilly's dulaglutide in late-stage study in type 2 di..
08/16 Emisphere's Prudent Move
08/16 Novo Nordisk goes ex-dividend tomorrow
08/15 Novo's traditional innovation model worked until it didn't - WSJ
08/15 20 Dividend Growth Stocks With Growth
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 31
Average target price 287  DKK
Spread / Average Target -1,7%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Göran Albert Ando Chairman
Jesper Brandgaard Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Mads Krogsgaard Chief Science Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S12.29%90 454
JOHNSON & JOHNSON15.48%360 112
NOVARTIS10.59%220 515
ROCHE HOLDING LTD.5.37%218 264
PFIZER1.45%198 663
MERCK AND COMPANY5.05%171 005